AgomAb Therapeutics NV AGMB
—
10.51
(0.07)
(0.66%)
as of 25 Sep
- Market cap
- $521.1M
- P/E
- —
Follow AGMB
| Jun '26 | Dec '25 | Sep '25 | Dec '24 | |
|---|---|---|---|---|
Current Ratio |
12.88 | 6.52 | 13.99 | 19.05 |
Net Debt/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 |
Debt/Assets |
0.31% | 0.65% | 0.65% | 0.62% |
Debt/Equity |
0.00 | 0.01 | 0.01 | 0.01 |
Operating CF/Net income |
0.00 | 0.00 | 0.00 | 0.00 |
Capex/Depreciation |
0.00 | 0.04 | 0.00 | (2.17) |
Intangible Assets out of Total Assets |
0.10 | 0.19 | 0.17 | 0.14 |
Share Based Compensation of Revenue |
0.00% | — | — | — |
Free Cash Flow per Share |
0.00 | 0.00 | 0.00 | 0.00 |
Cash per Share |
0.00 | 0.00 | 0.00 | 0.00 |
Shareholders Equity per Share |
0.00 | 0.00 | 0.00 | 0.00 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
0.00 | 0.00 | 0.00 | 0.00 |
Free Cash Flow |
(34.78) | (13.46) | (45.08) | (51.40) |
Working Capital |
277.20 | 116.14 | 144.36 | 178.24 |
Capital Expenditures |
— | 0.00 | — | (0.73) |
Net Current Asset Value |
270.83 | 111.37 | 133.62 | 168.34 |
| Other line items | ||||
Quick Ratio |
12.55 | 6.27 | 13.63 | 18.79 |
Operating CF per Share |
0.00 | 0.00 | 0.00 | 0.00 |
Capex per Share |
— | 0.00 | — | 0.00 |
Capex to Sales |
— | 0.00 | — | 0.00 |
Columns are period end dates